

*Not for release to US wire services or distribution in the US*

## Extension of Retail Entitlement Offer

Radiopharm Theranostics Limited (ASX:RAD, “RAD” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, refers to its fully underwritten non-renounceable entitlement issue originally announced on 19 October 2022, of 1 New Share for every 3.55 Existing Shares held by Eligible Shareholders at an Offer Price of \$0.14 per New Share (together with one free attaching New Option for every New Share issued) (with full details set out in the Prospectus dated 19 October 2022 and the Supplementary Prospectus dated 20 October 2022).

The Company wishes to advise that the Closing Date of the Retail Entitlement Offer has been extended from 5:00 pm Sydney time on Friday, 11 November 2022 to 5:00 pm Sydney time on Friday, 18 November 2022. The Offer timetable has been revised as follows:

|  |                           |
|--|---------------------------|
| Retail Entitlement Offer closes (5.00 pm, Sydney time)   | Friday, 18 November 2022  |
| Announcement of results of the Retail Entitlement Offer and under-subscriptions                                      | Tuesday, 22 November 2022 |
| Allotment of New Shares issued under the Retail Entitlement Offer and New Options issued under the Entitlement Offer | Friday, 25 November 2022  |
| Despatch of holding statements for New Shares and New Options issued under the Retail Entitlement Offer              | Monday, 28 November 2022  |
| Normal ASX trading for New Shares issued under the Entitlement Offer commences                                       | Monday, 28 November 2022  |

**Phillip Hains**  
**Company Secretary**

### Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.